Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
Related Posts
Fu KA, Chan JM, Stepanyan K, Elting S, Manchanda A, Zea Vera AG, Vermillion M, Wilhalme H, Keener AM, Strowd RE 3rd. Education Research: A[...]
Prohl EG, Vaidya NK. Splenic Infarction in a Patient With Sickle Cell Trait Following High-Altitude Exposure. Cureus. 2025 Jan 14;17(1):e77438. doi: 10.7759/cureus.77438. PMID: 39949449; PMCID:[...]
Wu JT, Langford BJ, Shenoy ES, Carey E, Branch-Elliman W. Chatting new territory: large language models for infection surveillance from pilot to deployment. Infect Control[...]